Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 4, 2002, Pages 206-212

  Furlong, Terry ^a   Leisenring, Wendy ^a   Storb, Rainer ^a   Anasetti, Claudio ^a   Appelbaum, Frederick R ^a   Carpenter, Paul A ^a   Deeg, H Joachim ^a   Doney, Kristine ^a   Kiem, Hans Peter ^a   Nash, Richard A ^a   Sanders, Jean E ^a   Witherspoon, Robert ^a   Thompson, Dianne ^a   Martin, Paul J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Acute graft versus host disease; Hematopoietic stem cell transplantation; PUVA

Indexed keywords

ANTIBODY; CORTICOSTEROID; CYCLOSPORIN; METHOTREXATE; METHOXSALEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PSORALEN; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; ZINC OXIDE;

ACUTE DISEASE; ADOLESCENT; ADULT; ARTICLE; BODY SURFACE; CHILD; CONTROLLED STUDY; DISEASE COURSE; DRUG TOLERABILITY; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNE MEDIATED INJURY; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; ORGAN DONOR; PHOTOTOXICITY; PUVA; RADIATION EXPOSURE; RASH; RELATIVE; SKIN DISEASE; ALLOTRANSPLANTATION; BLOOD DISEASE; BONE MARROW TRANSPLANTATION; CONTACT DERMATITIS; DRUG RESISTANCE; IMMUNOLOGY; INFANT; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRESCHOOL CHILD; RADIATION INJURY; RECURRENT DISEASE; REFRACTORY ANEMIA WITH EXCESS BLASTS; RETROSPECTIVE STUDY; SAFETY; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; DERMATITIS, PHOTOTOXIC; DRUG RESISTANCE; EXANTHEMA; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISONE; PUVA THERAPY; RADIATION INJURIES; RECURRENCE; RETROSPECTIVE STUDIES; SAFETY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0035999676     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.pm12014809     Document Type: Article

References (37)

1. Analysis of 462 transplantations from unrelated donors facilitated by The National Marrow Donor Program
2. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma
3. A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment
4. A retrospective analysis of therapy for acute graft-versus-host disease: Secondary treatment
5. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome
6. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin
7. Poor outcome in steroid refractory GVHD with ATG treatment
8. Mycophenolate mofetil (MMF) as salvage treatment for graft-versus-host-disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT): Safety analysis
9. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody, ABX-CBL
10. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
11. Infliximab for the treatment of graft-versus-host disease in allogeneic transplant recipients: An update
12. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease
13. Modification of allointeractions after blood transfusion and marrow transplantation by ultraviolet light
14. Phototherapy and photochemotherapy: An update
15. Treatment of moderate to severe acute graft-versus-host disease: A retrospective analysis
16. Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): Results of a pilot study
17. 8-methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease
18. PUVA as adjuvant primary or salvage treatment for chronic graft-versus-host disease (GVHD)
19. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA)
20. Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease
21. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia
22. A proposed objective way to assess results of randomized prospective clinical trials with acute graft-versus-host disease as an outcome of interest
23. UV-related skin conditions and Langerhans' cell populations in human skin
24. Studies on the effects of a high dose UVA-1 radiation therapy on surface markers and function of epidermal Langerhans cells
25. + T helper 1 cells
26. + Langerhans cells exhibit normal function
27. Activation of keratinocytes with psoralen plus UVA radiation induces the release of soluble factors that suppress delayed and contact hypersensitivity
28. Local suppression of contact hypersensitivity in mice by a monofunctional psoralen plus UVA radiation
29. + T cells during "long-term" PUVA treatment for psoriasis
30. Reduction of the fraction of circulating helper-inducer T cells identified by monoclonal antibodies in psoriatic patients treated with long-term psoralen/ultraviolet-A radiation (PUVA)
31. Immunomodulation induced by psoralen plus ultraviolet A radiation
32. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance
33. Does exposure to UV radiation induce a shift to a Th-2-like immune reaction?
34. Cytokine release by peripheral blood mononuclear cells is affected by 8-methoxypsoralen plus UV-A
35. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors
36. Psoralen photochemotherapy
37. Oral methoxsalen photochemotherapy for the treatment of psoriasis: A cooperative clinical trial